| 產品貨號 |
產品名稱 |
CAS |
規格 |
| B21920 |
L-精氨酸 |
74-79-3 |
分析標準品,HPLC≥98% |
摘要：The major challenges of immunotherapy for glioblastoma are that drugs cannot target tumor sites accurately and properly activate complex immune responses. Herein, we design and prepare a kind of chemotactic nanomotor loaded with brain endothelial cell targeting agent angiopep-2 and anti-tumor drug (Lonidamine modified with mitochondrial targeting agent triphenylphosphine, TLND). Reactive oxygen species and inducible nitric oxide synthase (ROS/iNOS), which are specifically highly expressed in glioblastoma microenvironment, are used as chemoattractants to induce the chemotactic behavior of the nanomotors. We propose a precise targeting strategy of brain endothelial cells-tumor cells-mitochondria. Results verified that the released NO and TLND can regulate the immune circulation through multiple steps to enhance the effect of immunotherapy, including triggering the immunogenic cell death of tumor, inducing dendritic cells to mature, promoting cytotoxic T cells infiltration, and regulating tumor microenvironment. Moreover, this treatment strategy can form an effective immune memory effect to prevent tumor metastasis and recurrence.
文獻鏈接：https://www.nature.com/articles/s41467-022-35709-0
| 貨號 |
產品名稱 |
CAS |
規格 |
| B21057 |
人參皂苷Rg1 |
22427-39-0 |
分析標準品,HPLC≥98% |
| B21055 |
人參皂苷Re |
52286-59-6 |
分析標準品,HPLC≥98% |
| B21056 |
人參皂苷Rf |
52286-58-5 |
分析標準品,HPLC≥98% |
| B21050 |
人參皂苷Rb1 |
41753-43-9 |
分析標準品,HPLC≥98% |
| B21053 |
人參皂苷Rc |
11021-14-0 |
分析標準品,HPLC≥98% |
| B21068 |
人參皂苷Ro |
34367-04-9 |
分析標準品,HPLC≥98% |
| B21051 |
人參皂苷Rb2 |
11021-13-9 |
分析標準品,HPLC≥98% |
| B21052 |
人參皂苷Rb3 |
68406-26-8 |
分析標準品,HPLC≥97% |
| B21054 |
人參皂苷Rd |
52705-93-8 |
分析標準品,HPLC≥98% |
| B21099 |
三七皂苷R1 |
80418-24-2 |
分析標準品,HPLC≥98% |
摘要：Panax ginseng (PG) and Panax notoginseng (PN) are highly valuable Chinese medicines (CM). Although both CMs have similar active constituents, their clinical applications are clearly different. Over the past decade, RNA sequencing (RNA-seq) analysis has been employed to investigate the molecular mechanisms of extracts or monomers. However, owing to the limited number of samples in standard RNA-seq, few studies have systematically compared the effects of PG and PN spanning multiple conditions at the transcriptomic level. Here, we developed an approach that simultaneously profiles transcriptome changes for multiplexed samples using RNA-seq (TCM-seq), a high-throughput, low-cost workflow to molecularly evaluate CM perturbations. A species-mixing experiment was conducted to illustrate the accuracy of sample multiplexing in TCM-seq. Transcriptomes from repeated samples were used to verify the robustness of TCM-seq. We then focused on the primary active components, Panax notoginseng saponins (PNS) and Panax ginseng saponins (PGS) extracted from PN and PG, respectively. We also characterized the transcriptome changes of 10 cell lines, treated with four different doses of PNS and PGS, using TCM-seq to compare the differences in their perturbing effects on genes, functional pathways, gene modules, and molecular networks. The results of transcriptional data analysis showed that the transcriptional patterns of various cell lines were significantly distinct. PGS exhibited a stronger regulatory effect on genes involved in cardiovascular disease, whereas PNS resulted in a greater coagulation effect on vascular endothelial cells. This study proposes a paradigm to comprehensively explore the differences in mechanisms of action between CMs based on transcriptome readouts.
文獻鏈接：https://www.sciencedirect.com/science/article/pii/S2095177923000242